Suggested treatments for eosinophilic esophagitis include PPIs, topical steroids, empiric food elimination diet, biologics, endoscopic dilation
FRIDAY, Jan. 24, 2025 (HealthDay News) — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are presented for the diagnosis and management of eosinophilic esophagitis (EoE).
Evan S. Dellon, M.D., M.P.H., from the University of North Carolina School of Medicine in Chapel Hill, and colleagues made recommendations across domains of diagnosis, treatment, monitoring, and assessment of response and pediatric-specific considerations for EoE.
The authors recommend that EoE is diagnosed based on the presence of symptoms of esophageal dysfunction and at least 15 eosinophils per high-power field on esophageal biopsy. A systematic endoscopic scoring system is recommended to characterize endoscopic findings of EoE at every endoscopy. To assess for histologic features consistent with EoE, at least six esophageal biopsies from at least two esophageal levels should be obtained. Eosinophil counts should be quantified on esophageal biopsies from every endoscopy performed. Proton pump inhibitors (PPIs) are suggested as a treatment for EoE, while swallowed topical steroids are recommended as a treatment. Use of either fluticasone propionate or budesonide is suggested for patients with EoE treated with topical steroids. An empiric food elimination diet is suggested for EoE treatment, but currently available allergy testing to direct food elimination diets is not suggested. Dupilumab is suggested for individuals aged 12 years or older and for pediatric patients who are nonresponsive to PPI therapy. Omalizumab is not suggested for EoE treatment. For esophageal strictures causing dysphagia, endoscopic dilation is suggested as an adjunct to medical therapy.
“For all treatments, cost and insurance coverage should be considered on an individual basis because there are scant cost-effectiveness data to currently support decisions,” the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Outpatient Benzodiazepine Treatment Down in U.S. Adults From 2018 to 2022 
Diltiazem Linked to Increased Risk for Bleeding Complications in A-Fib 
Perioperative Enfortumab Vedotin + Pembrolizumab Tied to Improved Outcomes With Bladder Cancer 
Monthly Cabotegravir-Rilpivirine Injections Superior to Standard Oral ART for HIV With Adherence Challenges 
Umeclidinium-Vilanterol Tied to Better Outcomes Than Other LAMA-LABA Inhalers in Symptomatic COPD 
Oxybutynin Beats Placebo for Reducing ADT-Linked Hot Flashes in Prostate Cancer 
Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Use of Gout Medications 
Use of Meds for Mental Health Up in Children, Young Adults From 2001 to 2020 
